How Continuous Glucose Monitors Are Revealing New Links Between Blood Sugar and Sleep Apnea
New research on the CGM sleep apnea correlation shows how nighttime glucose patterns can flag undiagnosed breathing problems
Millions of Europeans already wear a continuous glucose monitor for diabetes care, and a growing body of research suggests the same overnight data can also hint at an unrecognized breathing problem.
What the CGM Sleep Apnea Correlation Actually Shows in the Research
The CGM sleep apnea correlation is the pattern researchers now see between overnight glucose swings recorded on a continuous glucose monitor (CGM) and undiagnosed or poorly controlled obstructive sleep apnea (OSA). A CGM is a small skin sensor, worn day and night, that tracks blood sugar every few minutes and was originally built for people managing diabetes. When sleep apnea repeatedly narrows or closes the airway during sleep, it is linked to stress-hormone surges and drops in blood oxygen that show up as unusual glucose trends on the very same graph, which is why metabolically-aware users are increasingly reading their overnight CGM data for early breathing-related clues, not just insulin dosing.
The relationship runs in both directions. Poor sleep and low oxygen are associated with higher blood sugar readings, and sleep apnea and type 2 diabetes are now understood to feed into each other rather than being two unrelated conditions that happen to overlap. A 2025 peer-reviewed European review found that obstructive sleep apnoea syndrome (OSAS) disturbs glycaemic variability, meaning how much blood sugar swings up and down, "irrespective of glycaemic status" — so the pattern shows up even in people who are not diabetic (Gouveri et al., Diabetes Therapy, Democritus University of Thrace, Greece, 2025). This article walks through what the science actually says, how to read your own CGM traces, and where a self-care step such as improving nasal airflow realistically fits versus when the data means it is time to see a doctor.
The Scale of the Problem Across Europe
Obstructive sleep apnea is far more common across the EU than most people realize, and it is rising. Population modeling presented at the European Respiratory Society (ERS) Congress puts the number of Europeans with OSA of any severity at roughly 175 million, with about 90 million living with moderate-to-severe disease, defined as 15 or more breathing interruptions per hour of sleep (Benjafield et al., ERS Congress / Lancet Respiratory Medicine, 2018-2019). The same modeling work revised the global estimate upward to 936 million adults, nearly ten times the World Health Organization's 2007 estimate of 100 million.
The overlap with metabolic health is just as striking. A systematic review and meta-analysis estimated that 56.0% of people with type 2 diabetes also have obstructive sleep apnea (Sleep Science and Practice, BioMed Central, 2022). Looking forward, ERS congress research projects that OSA prevalence (AHI≥5, meaning five or more breathing events per hour) across the EU-5 countries — France, Germany, Italy, Spain, and the UK — will climb from 33.1% (51.3 million cases) in 2020 to 52.3% (76.6 million cases) by 2050, largely driven by rising obesity rates and an aging population (ERS, 2025).
- Roughly 1 in 2 people with type 2 diabetes in Europe is estimated to also have obstructive sleep apnea.
- OSA prevalence across the five largest EU economies is projected to nearly double by 2050.
- Glucose variability linked to OSA appears even in non-diabetic people, which is why CGM users without a diabetes diagnosis are noticing it too.
How Sleep Apnea Is Linked to Blood Sugar Changes Overnight
Sleep apnea is linked to blood sugar changes through repeated drops in oxygen and repeated stress-hormone surges, not through a single mechanism. Each time the airway narrows or briefly closes, blood oxygen falls, and the body responds as if under mild, repeated physical stress. That pattern is associated with releases of cortisol and adrenaline, which are linked to the liver releasing more glucose into the bloodstream, and to reduced insulin sensitivity in muscle and fat cells over time. Sleep fragmentation itself compounds the effect, since deep sleep is when the body is normally most efficient at regulating glucose overnight.
A 2020 study using continuous glucose and oxygen monitoring found that people with moderate-to-severe OSA showed a significant increasing trend in glucose after sleep onset, compared with a decreasing trend in people with no or mild OSA, alongside markedly lower overnight oxygen saturation — 76.0% versus 88.6% (p<0.001) (Scientific Reports, Nature, 2020). In plain terms, healthy sleepers' blood sugar tends to drift gently down overnight; in moderate-to-severe OSA, it can trend the opposite way while oxygen levels repeatedly dip well below the normal range.
Reading Your CGM for Overnight Patterns Linked to Sleep Apnea
Not every overnight glucose rise means sleep apnea, so it helps to know which CGM patterns are worth a closer look. The two most commonly confused patterns are the dawn phenomenon, a normal hormone-driven glucose rise in the early morning hours, and a nocturnal rise associated with disrupted breathing, which tends to track with snoring, gasping, or restless movement rather than the clock.
| CGM Pattern | Typical Timing | Usual Cause | When to Suspect a Link to OSA |
|---|---|---|---|
| Dawn phenomenon | 4-8am, consistent night to night | Normal cortisol/growth hormone rise | Low suspicion if isolated to early morning and stable |
| Erratic nocturnal variability | Scattered swings through the night | Fragmented sleep, repeated oxygen dips | Higher suspicion, especially with snoring or a bed partner reporting pauses in breathing |
| Exaggerated post-meal (dinner) spike | 2-4 hours after evening meal, extending into sleep | Late eating, reduced insulin sensitivity from poor sleep | Moderate suspicion if it worsens on poor-sleep nights |
| Rising trend after sleep onset | Begins soon after falling asleep, climbs rather than falls | Repeated airway narrowing and oxygen drops | High suspicion, closely matches the pattern reported in moderate-to-severe OSA |
A single odd night rarely means much, since CGM data is noisy and affected by food, stress, alcohol, and exercise. What is more informative is a repeating pattern across several nights, especially one that lines up with nights you or a partner notice loud snoring, gasping, or breathing pauses. Pairing that pattern with a validated screening questionnaire, such as the widely used STOP-Bang tool, gives a far more reliable signal than glucose data alone.
The European Research Behind the CGM Sleep Apnea Correlation
The strongest evidence for the CGM sleep apnea correlation comes from a Danish randomized controlled trial that paired CGM readings with an objective sleep apnea diagnosis. In a 12-week trial of 72 patients with type 2 diabetes and moderate-to-severe OSA (average AHI 35±15 events per hour), the group treated with CPAP therapy saw CGM-measured time-in-target glucose range improve by +3.4 percentage points, while the untreated control group's time-in-range worsened by -6.7 points (Endocrinology, Diabetes & Metabolism, Denmark, 2020). Notably, the change in the longer-term blood sugar marker HbA1c was not statistically significant over the 12 weeks, a reminder that CGM trends and lab markers do not always move in lockstep on short timelines.
Findings from the European Sleep Apnea Database (ESADA) cohort, one of the largest sleep clinic registries in Europe, have similarly linked more severe OSA with poorer metabolic markers, reinforcing that severity matters: the association is strongest in moderate-to-severe disease and much weaker in mild OSA or simple snoring. This severity gradient is central to interpreting your own CGM data sensibly, since it means a subtle nighttime glucose wobble in an otherwise healthy sleeper is a very different signal from a pronounced, repeating rise in someone who already snores heavily and feels exhausted during the day.
- CPAP therapy improved CGM time-in-range in a controlled trial, but did not significantly move HbA1c over 12 weeks.
- The glucose-OSA link is strongest in moderate-to-severe apnea, not simple snoring or mild cases.
- CGM trends should be read alongside sleep symptoms, not as a stand-alone diagnostic tool.
CGM Access, Data Privacy, and OSA Burden Across EU Countries
Access to CE-marked CGM systems and reimbursement rules still vary considerably by country within the EU, which matters for anyone trying to act on a CGM-flagged pattern. Some national health systems cover CGM use mainly for insulin-treated diabetes, while people without a diabetes diagnosis who buy a CGM out of pocket to monitor general metabolic health typically pay for the sensors themselves. Modern sleep-tracking and diagnostic tools are increasingly being layered on top of this data; AI-assisted tools are already changing how clinicians triage suspected sleep apnea cases, including flagging patients whose wearable or CGM data warrants a referral for a proper sleep study.
Combining a glucose app with a sleep-tracking app also raises a practical privacy question EU readers should not ignore. Under GDPR, health data, including glucose readings and sleep metrics, is classed as a "special category" of personal data requiring explicit consent and stronger protection, so it is worth checking that any app syncing your CGM with sleep data is transparent about where that combined dataset is stored and who can access it.
Country-level OSA burden also differs widely across the region. National breakdowns of the same global modeling data referenced above put the estimated number of people affected by OSA of some severity at roughly 26 million in Germany, 24 million in France, 9 million in Spain, and 8 million in the UK (Benjafield et al., 2019); these are population-level estimates, not confirmed diagnoses, since most OSA remains undiagnosed. Regardless of country, the diagnostic pathway is broadly similar: a validated symptom screener, followed by a home sleep apnea test or in-lab polysomnography, is the recognized route to a real diagnosis. CGM data can prompt that conversation, but it cannot replace it.
From CGM Pattern to Action: A Practical Decision Path
The right next step depends entirely on severity, so matching your CGM signal to a proper screening step matters more than reacting to any single night's data.
1Screen before you act
If you notice a repeating nocturnal glucose rise alongside snoring or witnessed breathing pauses, complete a validated screener such as STOP-Bang or the Berlin Questionnaire before assuming the cause.
2Get an objective sleep test
A low-to-moderate screener score paired with a home sleep apnea test, or a clinic-based polysomnography for a fuller picture, will show whether you have simple snoring, mild OSA (AHI 5-15), or something more severe that needs prompt medical attention.
3Match the treatment to the result
For confirmed simple snoring or mild OSA, nasal breathing support and sleep hygiene are a reasonable first step. For moderate-to-severe OSA, especially alongside the glucose patterns described in the Danish and Greek research above, CPAP therapy remains the evidence-backed treatment and should be discussed with a sleep physician without delay.
For the mild end of that spectrum, reducing nasal airway resistance can meaningfully cut down mouth breathing and snoring during sleep. The Back2Sleep nasal stent is a CE-certified Class I device, a soft silicone insert placed in the nostrils that helps keep the nasal airway open through the night, sold without a prescription as a starter kit with four sizes. It is intended for snoring and mild-to-moderate OSA confirmed by a sleep test, not as a substitute for CPAP in moderate-to-severe cases. People already exploring other non-CPAP routes, including weight-management approaches, should note that newer weight-loss medications are also being studied for their effect on sleep apnea severity, though none of these approaches replace getting a proper diagnosis first.
| Feature | Simple Snoring / Mild OSA (AHI <15) | Moderate-to-Severe OSA (AHI ≥15) |
|---|---|---|
| Typical CGM pattern | Occasional, mild nocturnal variability | Consistent rising trend after sleep onset |
| Recommended first step | Nasal airflow support, sleep hygiene, weight and alcohol management | Referral to a sleep physician for CPAP or another prescribed therapy |
| Where a nasal stent fits | Reasonable non-prescription first step alongside sleep hygiene | Not appropriate as a stand-alone treatment; only as directed by a clinician alongside primary therapy |
| CGM's role | Useful early clue to prompt screening | Supporting data point for the clinical team, not a treatment guide |
- Mild snoring or mild OSA confirmed by testing: nasal airflow support plus sleep hygiene is a sensible first step.
- Moderate-to-severe OSA: CGM patterns are a reason to see a doctor about CPAP, not to self-treat.
- A nasal stent is never a substitute for CPAP once moderate-to-severe OSA is confirmed.
What Back2Sleep Users Say
Frequently Asked Questions
Can a CGM detect or diagnose sleep apnea?
A continuous glucose monitor cannot diagnose sleep apnea on its own. It can reveal overnight glucose patterns, such as a rising trend after sleep onset, that research links to moderate-to-severe OSA. Confirming a diagnosis still requires a validated screener plus a home sleep apnea test or in-clinic polysomnography.
Why does my glucose rise overnight on my CGM even when I haven't eaten?
An overnight rise with no food involved can come from the dawn phenomenon, stress, illness, or disrupted breathing. Studies associate a rise that starts soon after falling asleep and keeps climbing, rather than only in early morning, with moderate-to-severe obstructive sleep apnea and its oxygen and stress-hormone effects.
Does sleep apnea raise blood sugar even in people without diabetes?
A 2025 European review found obstructive sleep apnoea syndrome is associated with increased glycaemic variability "irrespective of glycaemic status," meaning the effect on blood sugar swings shows up in non-diabetic people too (Gouveri et al., Diabetes Therapy, 2025), not only in those already diagnosed with diabetes.
What percentage of people with type 2 diabetes also have obstructive sleep apnea?
A 2022 systematic review and meta-analysis estimated that 56.0% of people with type 2 diabetes also have obstructive sleep apnea (Sleep Science and Practice, 2022). The overlap is large enough that some clinicians now recommend sleep apnea screening as a routine part of type 2 diabetes management.
Does treating sleep apnea with CPAP actually improve glucose control?
A Danish randomized controlled trial found CPAP therapy improved CGM-measured time-in-target glucose range by 3.4 percentage points over 12 weeks, versus a decline in the untreated group. However, the change in HbA1c, a longer-term blood sugar marker, was not statistically significant in that same trial.
What CGM pattern should make me suspect sleep apnea instead of the normal dawn phenomenon?
The dawn phenomenon is a predictable rise limited to the early morning hours. A pattern more associated with sleep apnea starts soon after falling asleep, climbs rather than falls, and repeats on nights with heavier snoring, which is worth checking against a validated sleep apnea screener.
How do I get tested for sleep apnea if my CGM data suggests a problem?
Start with a validated screener such as STOP-Bang or the Berlin Questionnaire, then ask a doctor about a home sleep apnea test or in-clinic polysomnography. Costs and access vary by country across the EU, so check your national health system, Mutuelle, GKV, or NHS pathway before booking privately.
Can a nasal stent help with the glucose patterns I see on my CGM?
A nasal stent does not act on blood sugar directly. If a sleep test confirms simple snoring or mild OSA, a CE-certified nasal stent may reduce nasal resistance and mouth breathing as part of a broader plan, but moderate-to-severe OSA linked to larger glucose swings needs a CPAP evaluation first.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.